Skip to main content

Table 1 Characteristics of patients treated with tocilizumab therapy

From: CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis

 

Baseline (n = 36)

Week 12 (n = 36)

Week 24 (n = 36)

1 year (n = 36)

Age, median (range) years

54 (33-79)

   

% female

77%

   

Disease duration, median (range) years

9 (2-33)

   

RF positive

36

ACPA positive

28

RF/ACPA positive

28

 
 

mean ± SEM

   

DAS28 score

5.2 ± 0.3

3.3 ± 0.3ψ

2.7 ± 0.2ψ

1.9 ± 0.2ψ

CRP, mg/dl

0.9 ± 0.1

0.14 ± 0.06ψ

0.09 ± 0.03ψ

0.06 ± 0.02ψ

ESR, mm/hour

32.1 ± 3.4

9.8 ± 1.6ψ

7.2 ± 0.9ψ

5.6 ± 0.8ψ

Patient’s VAS

58.3 ± 4.4

48.6 ± 4.8ψ

34.8 ± 5.4ψ

21.5 ± 4.8ψ

IgA-RF U/ml

122.3 ± 33.3

99.9 ± 26.3ψ

63.3 ± 19.8ψ

-

IgA total U/ml

265.4 ± 20.8

237.2 ± 19.5ψ

203.1 ± 18.9ψ

-

  1. The primary end point of the study was a reduction in the disease activity score in 28 joints (DAS28) at week 12. Except where indicated otherwise, values are the mean ± standard error of the mean (SEM). ψ P <0.05 versus baseline and Mann-Whitney t test was used for statistics. RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analog scale (100 mm); IgA, immunoglobulin A.